Aytu BioPharma, Inc. (AYTU)
NASDAQ: AYTU · Real-Time Price · USD
1.490
-0.075 (-4.79%)
Nov 20, 2024, 4:00 PM EST - Market closed
Aytu BioPharma Income Statement
Financials in millions USD. Fiscal year is July - June.
Millions USD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2019 - 2015 |
| Revenue | 79.76 | 81 | 107.4 | 96.67 | 65.63 | 27.63 | Upgrade
|
| Revenue Growth (YoY) | -18.25% | -24.58% | 11.10% | 47.29% | 137.52% | 277.47% | Upgrade
|
| Cost of Revenue | 25.5 | 25.69 | 40.77 | 46.39 | 36.43 | 8.28 | Upgrade
|
| Gross Profit | 54.26 | 55.32 | 66.63 | 50.28 | 29.2 | 19.35 | Upgrade
|
| Selling, General & Admin | 47.87 | 49.47 | 70.08 | 69.88 | 55.81 | 31.06 | Upgrade
|
| Research & Development | 2.62 | 2.79 | 4.1 | 12.66 | 5.62 | 1.72 | Upgrade
|
| Operating Expenses | 55.7 | 57.48 | 78.96 | 88.39 | 67.44 | 37.27 | Upgrade
|
| Operating Income | -1.44 | -2.16 | -12.33 | -38.1 | -38.24 | -17.92 | Upgrade
|
| Interest Expense | -4.5 | -4.79 | -4.96 | -0.01 | -0.01 | - | Upgrade
|
| Other Non Operating Income (Expenses) | 5.31 | -3.44 | 4.98 | 0.86 | -2.04 | -2.6 | Upgrade
|
| EBT Excluding Unusual Items | -0.63 | -10.39 | -12.32 | -37.26 | -40.29 | -20.53 | Upgrade
|
| Merger & Restructuring Charges | -3.88 | -3.1 | - | - | -7.81 | -3.02 | Upgrade
|
| Impairment of Goodwill | - | - | - | -65.8 | - | - | Upgrade
|
| Asset Writedown | - | - | -5.71 | -7.66 | -12.83 | -0.2 | Upgrade
|
| Other Unusual Items | -0.59 | -0.59 | 0.97 | 1.82 | 2.89 | 10.11 | Upgrade
|
| Pretax Income | -5.11 | -14.08 | -17.05 | -108.89 | -58.03 | -13.62 | Upgrade
|
| Income Tax Expense | 2.17 | 1.77 | - | -0.11 | 0.26 | - | Upgrade
|
| Net Income | -6.25 | -15.84 | -17.05 | -108.78 | -58.29 | -13.62 | Upgrade
|
| Net Income to Common | -6.25 | -15.84 | -17.05 | -108.78 | -58.29 | -13.62 | Upgrade
|
| Shares Outstanding (Basic) | 6 | 6 | 3 | 1 | 1 | 0 | Upgrade
|
| Shares Outstanding (Diluted) | 6 | 6 | 3 | 1 | 1 | 0 | Upgrade
|
| Shares Change (YoY) | 39.29% | 65.81% | 127.22% | 75.54% | 270.57% | 479.80% | Upgrade
|
| EPS (Basic) | -1.10 | -2.86 | -5.11 | -74.01 | -69.61 | -60.28 | Upgrade
|
| EPS (Diluted) | -1.61 | -2.86 | -5.11 | -74.01 | -69.61 | -60.28 | Upgrade
|
| Free Cash Flow | -2.5 | -1.39 | -5.13 | -28.82 | -28.31 | -28.37 | Upgrade
|
| Free Cash Flow Per Share | -0.44 | -0.25 | -1.54 | -19.61 | -33.80 | -125.57 | Upgrade
|
| Gross Margin | 68.03% | 68.29% | 62.04% | 52.02% | 44.49% | 70.03% | Upgrade
|
| Operating Margin | -1.80% | -2.67% | -11.48% | -39.42% | -58.26% | -64.86% | Upgrade
|
| Profit Margin | -7.84% | -19.56% | -15.88% | -112.53% | -88.81% | -49.29% | Upgrade
|
| Free Cash Flow Margin | -3.14% | -1.71% | -4.78% | -29.82% | -43.13% | -102.69% | Upgrade
|
| EBITDA | 6.42 | 6.11 | -3.51 | -27.96 | -29.04 | -12.21 | Upgrade
|
| EBITDA Margin | 8.05% | 7.55% | -3.27% | -28.92% | -44.25% | -44.18% | Upgrade
|
| D&A For EBITDA | 7.86 | 8.27 | 8.82 | 10.15 | 9.2 | 5.71 | Upgrade
|
| EBIT | -1.44 | -2.16 | -12.33 | -38.1 | -38.24 | -17.92 | Upgrade
|
| EBIT Margin | -1.80% | -2.67% | -11.48% | -39.42% | -58.26% | -64.86% | Upgrade
|
| Advertising Expenses | - | 4.88 | 17.22 | 13.6 | 15.2 | 4.7 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.